Roche Pharmaceutical Development and Sales Overview
YTD Sep 2022: Diagnostics Division CER growth
By Region and Customer Area (vs. 2021)
Roche
Reported
Restatement³
Global
EMEA¹
NOA
CHFM %CER CHFm %CER CHFM %CER
APAC
LATAM
CHFm %CER CHFm %CER
Global
CHFm %CER CHFm %CER
EMEA¹
NOA
CHFm %CER
APAC
LATAM
CHFm %CER CHFm %CER
Core Lab 2,3
Point of Care³
5,772 5 1,913 6
2,610
1,072 2
2,354 6
433 11
5,833 5
1,971 5
1,074 2
2,355
6
433
11
29 660
-54
868
421
994 386
88 -45
3,086 30
753
-51
1,135 192
1,106 357
92 -43
Molecular Lab³
3,272 -3
1,133
-4
1,279
-5
769
4
91
-26
2,735
-8
982
-4
1,010
-10
656 -7
87 -28
Diabetes Care
Pathology Lab
1,219
-3
652
-3
181
-21
209
1
177 25
1,219
-3
652 -3
181
-21
209
1 177 25
975
10
237
11
523
9
196
13
110
19
29
975
10
237 11 523
9
196
13
19 29
22
Diagnostics Div. 13,848
11 4,595 -14 3,923
34 4,522
28
28
808
-3
13,848
6 4,595-13|| 3,923
20 4,522
28
808
-3
CER=Constant Exchange Rates; ' Europe, Middle East and Africa; 2 incl. Roche Information Solutions; 3 Sales in the Point of Care customer area include sales from the Liat business (POC molecular), and sales in the Core
Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC
molecular sales = 90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21-194mCHF. In Q1 21 LS Alliances = 21mCHF, Q2 21-23mCHF, Q3 21-23m CHF, Q4 21=20mCHF.
168View entire presentation